R&D | 20 September 2026
Croda opens global biotech R&D centre in UK
The new centre is also expected to strengthen links between Croda, universities, industry and government
The new centre is also expected to strengthen links between Croda, universities, industry and government
For researchers, the change could reduce the need to manually inspect documents when searching for compounds, structures and other chemical evidence
It gives startups, established companies and government partners access to pilot-scale equipment, engineering expertise, independent scientific validation and commercialization support
BASF and IRRI will shift their focus to soil health – particularly the role of carbon and nitrogen in the soil
PPG said its approach is increasingly extending beyond coatings themselves
The platform will develop industrial demonstrators that can subsequently be scaled at production facilities
The ICCF study is part of Hylenr’s broader research programme investigating heat generation, gas changes and the formation of new elements in hydrogen-loaded materials
The patented technology centres on a biodegradable, eco-friendly biofiller engineered from lignocellulosic biomass
29% of chemical and pharmaceutical companies expect their R&D spending in Germany to fall
AkzoNobel has invested more than €1.3 billion in research and development over the last five years
The deal includes a first purchase option worth more than $450 million over seven years
The Bengaluru-based initiative is designed to tackle a growing problem across research-driven industries
The development also signals a broader shift in India’s beauty and specialty chemicals ecosystem
Aims to bring molecular-level Isotope analysis to more labs
WISE is now commercially available as a liquid that can be UV-cured into virtually any shape
NSF MONET has focused on decoded the non-linear mechanics of these networks
Kureha is developing SiC fibers as a new business and is targeting both high quality and cost competitiveness through its proprietary manufacturing process
MC²+ Ignite is designed to tackle one of the biggest hurdles in deep-tech commercialisation
The expanded capabilities are designed to help Clariant respond faster to rapidly changing market trends
The formulation has potential applications in the treatment of several cancers, including breast and prostate cancers, particularly through oral administration
Subscribe to our newsletter & stay updated.
